Evidence map›Paper›PMID 23388508›Full record

Trial reportBritish journal of anaesthesia2013

Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery.

C Solomon, C Hagl, N Rahe-Meyer

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in British journal of anaesthesia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Thromboelastometric Monitoring of the Hemostatic Effect of Platelet Concentrates Transfusion in Thrombocytopenic Children Undergoing Chemotherapy.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2015
    Trial
  5. Trial
  6. Article
  7. Article
  8. Hypothermic circulatory arrest does not induce coagulopathy in vitro.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. [How I use fibrinogen replacement treatment in acquired bleeding].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018
    Article
  17. Article
  18. Observational
  19. Effects of Fibrinogen Concentrate on Thrombin Generation, Thromboelastometry Parameters, and Laboratory Coagulation Testing in a 24-Hour Porcine Trauma Model.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2016
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

C SolomonDepartment of Anaesthesiology and Intensive Care Medicine, SALK University Hospital, Salzburg, Austria. solomon.cristina@googlemail.com
C Hagl
N Rahe-Meyer

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is currently a contrast between the demonstrated benefits of fibrinogen concentrate in correcting bleeding and reducing transfusion, and its perceived thrombogenic potential. This analysis evaluates the effects of fibrinogen concentrate on coagulation up to 12 days after administration during aortic surgery.

methodsWe performed a post hoc analysis of a prospective, randomized, double-blind, controlled trial of fibrinogen concentrate as first-line haemostatic therapy in aortic surgery. After cardiopulmonary bypass (CPB) and protamine administration, subjects with coagulopathic bleeding received fibrinogen concentrate or placebo. The placebo group received allogeneic blood products, including fresh-frozen plasma (FFP; n=32); the fibrinogen concentrate group received fibrinogen concentrate alone (FC; n=14), or fibrinogen concentrate followed by allogeneic blood products (FC+FFP; n=15). Plasma fibrinogen, fibrin-based clotting (ROTEM(®)-based FIBTEM assay), and peri- and postoperative haematological and coagulation parameters were compared.

resultsPlasma fibrinogen and FIBTEM maximum clot firmness (MCF) decreased ∼50% during CPB but were corrected by FC or FC+FFP. At last suture, the highest values for plasma fibrinogen (360 mg dl(-1)) and FIBTEM MCF (22 mm) were within normal ranges--below the acute phase increases observed after surgery. In patients receiving only FFP as a source of fibrinogen, these parameters recovered marginally by last suture (P<0.001 vs FC and FC+FFP). All groups displayed comparable haemostasis at 24 h post-surgery. Fibrinogen concentrate did not cause alterations of other haemostasis parameters.

conclusionsFibrinogen concentrate provided specific, significant, short-lived increases in plasma fibrinogen and fibrin-based clot firmness after aortic surgery.

Indexed as

AdultAgedAged, 80 and overAortaCardiopulmonary BypassDouble-Blind MethodFemaleFibrinogenHemostaticsHumansMaleMiddle AgedProspective StudiesFibrinogenHemostaticsblood coagulation testscardiopulmonary bypassfibrinfibrinogenplasma

Identifiers

PMID23388508
PMCPMC3657602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.